Banque Cantonale Vaudoise reduced its holdings in shares of The Chemours Company (NYSE:CC – Get Rating) by 14.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,246 shares of the specialty chemicals company’s stock after selling 3,911 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Chemours were worth $712,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Lindbrook Capital LLC lifted its holdings in Chemours by 117.3% during the fourth quarter. Lindbrook Capital LLC now owns 969 shares of the specialty chemicals company’s stock worth $30,000 after acquiring an additional 523 shares during the period. CoreCap Advisors LLC purchased a new stake in Chemours in the fourth quarter worth $60,000. TCI Wealth Advisors Inc. increased its position in Chemours by 19.7% in the third quarter. TCI Wealth Advisors Inc. now owns 2,179 shares of the specialty chemicals company’s stock worth $54,000 after buying an additional 358 shares during the last quarter. Itau Unibanco Holding S.A. increased its position in Chemours by 35.6% in the fourth quarter. Itau Unibanco Holding S.A. now owns 2,935 shares of the specialty chemicals company’s stock worth $90,000 after buying an additional 770 shares during the last quarter. Finally, Harbor Investment Advisory LLC increased its position in Chemours by 20.1% in the fourth quarter. Harbor Investment Advisory LLC now owns 3,299 shares of the specialty chemicals company’s stock worth $101,000 after buying an additional 551 shares during the last quarter. 71.89% of the stock is currently owned by institutional investors.
Insider Activity at Chemours
In related news, insider Alisha Bellezza sold 27,716 shares of the stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $35.47, for a total transaction of $983,086.52. Following the completion of the sale, the insider now directly owns 43,931 shares in the company, valued at approximately $1,558,232.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.63% of the stock is currently owned by company insiders.
Chemours Price Performance
Chemours (NYSE:CC – Get Rating) last posted its quarterly earnings data on Friday, April 28th. The specialty chemicals company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.36. Chemours had a return on equity of 53.44% and a net margin of 7.45%. The firm had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same period in the prior year, the business earned $1.46 EPS. The company’s revenue for the quarter was down 12.9% compared to the same quarter last year. As a group, equities analysts anticipate that The Chemours Company will post 3.97 EPS for the current fiscal year.
Chemours Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Monday, May 15th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 3.57%. The ex-dividend date of this dividend is Friday, May 12th. Chemours’s dividend payout ratio is presently 32.26%.
Analysts Set New Price Targets
A number of research firms have issued reports on CC. Royal Bank of Canada raised their target price on Chemours from $35.00 to $36.00 in a research report on Monday, May 1st. The Goldman Sachs Group lifted their price target on Chemours from $34.00 to $38.00 and gave the company a “neutral” rating in a research report on Tuesday, February 14th. StockNews.com cut Chemours from a “buy” rating to a “hold” rating in a research report on Saturday, May 20th. Citigroup lifted their price target on Chemours from $33.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, February 13th. Finally, Credit Suisse Group reduced their price target on Chemours from $27.00 to $25.00 in a research report on Friday, April 28th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $36.11.
The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.
- Get a free copy of the StockNews.com research report on Chemours (CC)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC – Get Rating).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.